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Background
Bovine tuberculosis (TB) is a disease which constitutes
an important economic and zoonotic problem in Latin
America. The etiological agent, Mycobacterium bovis,
has several antigens described and well characterized.
The M. bovis antigen 85B (Ag85B), encoded by fbpB
gene, is the bacillus immunodominant antigen and pro-
mising target for vaccine and diagnosis development [1].
Ag85B combined with other immunogens is considered
as a potential diagnostic tool for TB ELISA assay [2].
Anti-Ag85B antibodies have high sensitivity and specifi-
city for mycobacteria detection in commercial tests [3].
Here we describe the recombinant Ag85B production by
Mycobacterium smegmatis, a fast growing mycobacterial
specie.
Methods
Two pairs of synthetic oligonucleotide primers were
designed using the Vector NTI software, based on the M.
bovis AF2122/97 complete genome sequence. The histi-
dine tail codons were included in the reverse primers in
order to facilitate recombinant proteins purification by
nickel affinity columns. These primers were used for
PCR amplication of fbpB gene, including its own promo-
ter (1500 bp) and one immunodominant portion
(873 bp) of the same gene. The PCR products were
digested with KpnI, and XbaI and HindIII, respectively.
The digestion products were then cloned into the respec-
tive mycobacterial expression vectors: pUP410 and
pUS2000, which were previously digested with the same
restriction enzymes. The ligations were transformed by
electroporation into E. coli TOP 10 competent cells and
transformed cells were selected on LB agar medium con-
taining kanamycin. The recombinant plasmids were
extracted using the QIAprep® Spin Miniprep Kit
(Qiagen). To confirm the fbpB gene cloning, the recom-
binant vectors were digested with XhoI restriction
enzyme, which has a restriction site within the cloned
fragment and vectors. M. smegmatis mc2 eletrocompe-
tent cells were transformed with recombinant vectors,
grown for 3 hours at selective medium (7H9 medium
supplemented with 10% OADC, 0.2% glycerol and 0.05%
Tween 80) containing kanamycin. The cultures were cen-
trifuged, the pellet suspended in 50 mM Tris-HCl buffer
and lysed by sonification. The soluble and insoluble frac-
tions were separated by centrifugation. The Ag85B
expression was detected by western blot employing
mouse polyclonal anti-Ag85B and anti-histidine
antibodies.
Results and conclusions
The internal cleavage of recombinants vectors by XhoI
confirmed the fbpB cloning into pUP410 and pUS2000.
The recombinant antigen expression with expected mole-
cular mass was observed in the soluble fraction of recom-
binant M. smegmatis. When the expression was compared
to negative controls (cell extracts of BCG Pasteur and
M. smegmatis mc2), we observed a more pronounced
Ag85B expression at western blot employing mouse poly-
clonal anti-Ag85B. High levels of expression of Ag85B
occurred because pUP410 and pUS2000 have strong
mycobacterial promoters and are epissomal vectors which
are present in number of five copies per transformed cell
[4]. Moreover, western blot employing anti-histidine anti-
bodies demonstrated antigen expression at recombinant
M. smegmatis, but not at negative controls. The recombi-
nant antigen production by M. smegmatis will enable the
subsequent purification and production of polyclonal and
monoclonal antibodies against Ag85B.
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